Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.
Shabnam Hossein, Manivel Rengasamy, Aiyedun Uzamere, Crystal Spotts, Robert H Howland, Meredith L Wallace, Sanjay J. Mathew, Rebecca B Price
The British journal of psychiatry : the journal of mental science May 13, 2025 DOI: 10.1192/bjp.2024.276 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 152 |
| Population | Adults with treatment-resistant depression |
| Intervention | Intravenous ketamine |
| Dose | 0.5 mg/kg |
| Duration | Single 40-minute infusion, with follow-up up to 30 days post-infusion |
| Topics | Depression Ketamine Esketamine |
| Keywords | Biological Out-patient treatment Randomised controlled trial Depression treatment Clinical trials Antidepressant medication Mood disorders Mental health therapy |
| Citations | 3 |
| Key findings | Ketamine produced the greatest early improvement in sadness, while suicidal ideation improved later, and it increased symptom network connectivity. |
Abstract
Understanding the effects of ketamine on depressive symptoms could help identify which patients might benefit and clarify its mechanism of action in both the early (≤1 day post-infusion) and late (e.g. 2-30 days post-infusion) post-infusion periods. Symptom network analyses could provide complementary information regarding relationships between symptoms. To identify the effects of ketamine on symptom-level changes in depression across both the early and late post-infusion periods and on depressive symptom network changes. In this secondary analysis of 152 adults with treatment-resistant depression (with 38.8% reporting suicidal ideation at baseline), we compared symptom changes in the early and late post-infusion periods between individuals randomised to a single 40 min infusion of intravenous ketamine 0.5 mg/kg (n = 103) or saline (n = 49) and identified changes in symptom networks between pre- and post-ketamine treatment using network analyses. In the early post-infusion period, the greatest improvement (comparing ketamine with saline) was in depressive symptoms related to sadness. In network analyses, symptom network connectivity increased following ketamine infusion. Symptoms of sadness and lassitude showed persistent improvement in the first week post-infusion, whereas improvements in suicidal thoughts first emerged 3-4 weeks post-infusion. Ketamine improved all symptoms but showed the greatest effect on symptoms of sadness, both immediately and in the initial week after treatment. Ketamine also rapidly altered the topology of symptom networks, strengthening interrelationships between residual symptoms. The efficacy of ketamine (compared with saline) regarding suicidal symptoms emerged later. Our findings suggest potentially divergent efficacy, time courses and mechanisms for different symptoms of depression.
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.